- The mTOR in PTC without BRAF-V600E mutation 0.26 (0.01; 1.00) vs. 42.72 (12.42; 361.00) in PTC with BRAF-V600E mutation (p < 0.05) = significantly higher expression in PCT with BRAF-V600E mutation.- BRAF gene status did not match in the cancers and metastases (Primary tumor and metastasis have the same status BRAF-V600E vs. Primary tumor and metastasis have heterogenous BRAF-V600E) = significantly higher expression of mTOR in heterogenous status mTOR 0.07 (0.01; 0.46) 2.30 (1.00; 653.00). This evidence concerns the gene MTOR and cancer.